What are the key drivers of Schering-Plough's revenue growth in this period?

Revenue growth was primarily driven by strong performance in its Prescription Pharmaceuticals segment, with notable contributions from products like REMICADE, NASONEX, and TEMODAR. Growth in the Consumer Health Care and Animal Health segments also contributed positively. The company also noted favorable impacts from foreign exchange rates.

How is Schering-Plough financing its planned acquisition of Organon BioSciences?

Schering-Plough has raised significant capital through various financing activities. This includes approximately $6.0 billion from debt and equity offerings in the third quarter of 2007, and further debt issuances of approximately $2.8 billion in early October 2007. The company also has available credit facilities and intends to utilize existing cash and short-term investments.

What is the status of the legal and regulatory matters mentioned in the filing?

The company settled a significant investigation with the U.S. Attorney’s Office for the District of Massachusetts for $435 million. Additionally, the Consent Decree with the FDA, related to manufacturing practices, was dissolved in August 2007. However, other legal proceedings and investigations, including patent disputes and securities litigation, are ongoing.

How is the Merck/Schering-Plough cholesterol joint venture performing?

The joint venture, which manages VYTORIN and ZETIA, continues to perform strongly, with sales growth attributed to increased market share. Equity income from the joint venture for the quarter increased by 29.7% to $506 million, reflecting the positive sales trend.

MRK 10-Q Quarterly Report Q3 FY2007 — Revenue, Net Income, EPS

Summary

Merck & Co., Inc. (MRK) (referred to as Schering-Plough in this filing) reported its third quarter and nine-month results for the period ending September 30, 2007. The company demonstrated significant revenue growth, with net sales increasing by 9% year-over-year for the quarter and 13% for the nine months, reaching $2.8 billion and $9.0 billion, respectively. This growth was driven by strong performance across its Prescription Pharmaceuticals, Consumer Health Care, and Animal Health segments, with key products like REMICADE, NASONEX, and TEMODAR showing notable sales increases. The company also reported a substantial increase in net income available to common shareholders, rising from $287 million in the prior year's quarter to $713 million in the current quarter, partly due to significant mark-to-market gains on foreign currency options. The company is actively pursuing strategic initiatives, including the planned acquisition of Organon BioSciences, which was announced in March 2007. To finance this acquisition and other activities, Schering-Plough has successfully raised substantial capital through significant debt and equity offerings during the quarter. Despite ongoing legal and regulatory matters, including a $435 million settlement related to the Massachusetts Investigation, the company appears to be strengthening its financial position and investing in its future growth through R&D and strategic acquisitions.

Key Highlights

1Net sales increased by 9% year-over-year to $2.8 billion for the third quarter and 13% to $9.0 billion for the nine months ended September 30, 2007.
2Net income available to common shareholders significantly increased to $713 million for the quarter, up from $287 million in the prior year period.
3The company is proceeding with the planned acquisition of Organon BioSciences, a significant strategic move.
4Substantial capital was raised through debt and equity offerings, totaling approximately $6.0 billion in the third quarter, to fund the acquisition and other corporate purposes.
5The company reported a $435 million settlement for the Massachusetts Investigation during the nine-month period.
6The joint venture with Merck for cholesterol-lowering drugs (VYTORIN and ZETIA) continues to perform well, with equity income increasing by 29.7% to $506 million for the quarter.
7R&D spending increased significantly by 25% in the quarter and 33% year-to-date, reflecting investment in pipeline development and licensing.

Merck & Co., Inc. Quarterly Report for Q3 Ended Sep 30, 2007

Summary

Key Highlights

Frequently Asked Questions